Solar 18 Corporation (SLRN)
May 21, 2025 - SLRN was delisted (reason: merged into ALMS)
2.250
-0.020 (-0.88%)
Inactive · Last trade price on May 21, 2025
Acelyrin Revenue
In the year 2005, Acelyrin had annual revenue of $250.00M.
Revenue (ttm)
$250.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
83
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2005 | 250.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSLRN News
- 6 months ago - ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - GlobeNewsWire
- 6 months ago - Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis - GlobeNewsWire
- 6 months ago - ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - GlobeNewsWire
- 7 months ago - ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN - Business Wire
- 8 months ago - ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - GlobeNewsWire
- 8 months ago - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger - GlobeNewsWire
- 8 months ago - ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - GlobeNewsWire
- 9 months ago - ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences - GlobeNewsWire